Patent ID: 8257726

Claim:
A system for providing controlled release delivery of drugs for inhibiting neointimal hyperplasia in a blood vessel, comprising: a composition including a plurality of therapeutic substances including zotarolimus or salts or prodrugs thereof; and paclitaxel or salts or prodrugs thereof; wherein the activities of said therapeutic agent(s) are complementary; wherein the prodrug of paclitaxel is an ester formed from paclitaxel and a group selected from the group consisting of acetyl, proprionyl, pivaloyl, pivaloyloxymethyl, acetoxymethyl, phthalidyl, methoxymethyl, indanyl, natural and non-natural amino acids; wherein the prodrug of zotarolimus is an ester formed from zotarolimus and a group selected from the group consisting of acetyl, proprionyl, pivaloyl, pivaloyloxymethyl, acetoxymethyl, phthalidyl, methoxymethyl, indanyl, and natural and non-natural amino acids; or is of the following formula: wherein R=R 1 C(O)R 2 R 3 or R 1 C(S)R 2 R 3 where R 1 =O or S; R 2 =nothing, O, N, S, alkyl, alkenyl, alkynyl, heterocycles, or aryl; R 3 =nothing, alkyl, alkenyl, alkynyl, heterocycles, or aryl, wherein alkyl, alkenyl, alkynyl, heterocycles, aryl groups are substituted or unsubstituted; and wherein the composition is associated with a stent, wherein the ratio of zotarolimus:paclitaxel by weight is 10:7≦r≦10:0.1, wherein the loading of zotarolimus ranges from about 1 μg/mm to about 100 μg/mm of the stent and the loading of paclitaxel is 1 μg/mm of the stent.